 | • レポートコード：TPM-B04348 • 出版社/出版日：Transparency Market Research / 2017年10月 • レポート形態：英文、PDF、254ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、血漿プロテアーゼC1抑制剤の世界市場について調べ、血漿プロテアーゼC1抑制剤の世界規模、市場動向、市場環境、薬剤分類別分析、流通経路別分析、剤形別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・血漿プロテアーゼC1抑制剤の世界市場動向 ・血漿プロテアーゼC1抑制剤の世界市場環境 ・血漿プロテアーゼC1抑制剤の世界市場規模 ・血漿プロテアーゼC1抑制剤の世界市場規模：薬剤分類別 ・血漿プロテアーゼC1抑制剤の世界市場規模：流通経路別 ・血漿プロテアーゼC1抑制剤の世界市場規模：剤形別 ・血漿プロテアーゼC1抑制剤の世界市場：地域別市場規模・分析 ・血漿プロテアーゼC1抑制剤の北米市場規模・予測 ・血漿プロテアーゼC1抑制剤のアメリカ市場規模・予測 ・血漿プロテアーゼC1抑制剤の中南米市場規模・予測 ・血漿プロテアーゼC1抑制剤のヨーロッパ市場規模・予測 ・血漿プロテアーゼC1抑制剤のアジア市場規模・予測 ・競争状況・関連企業情報 |
Global Plasma Protease C1-inhibitor Treatment Market: Overview
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The plasma protease C1-inhibitors treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, dosage type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises Porters Five Forces analysis to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global plasma protease C1-inhibitors treatment market.
Global Plasma Protease C1-inhibitor Treatment Market: Market Segmentation
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.
Based on distribution channel, the plasma protease C1-inhibitors treatment market has been segmented into four major categories: hospital pharmacies, and independent pharmacies & outlets. The plasma protease C1-inhibitors treatment market is also segmented into dosage type lyophilized and liquid/injectable. The market segments have been extensively analyzed based on prevalence of the diseases, available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Geographically, the global plasma protease C1-inhibitors treatment market has been categorized into four major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (EU-5 Countries, BENELUX Countries, and Rest of Europe), Latin America (Brazil, Argentina, and Rest of Latin America) and Rest of World (Australia, Israel, and Rest of World Countries). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.
Global Plasma Protease C1-inhibitor Treatment Market: Competitive Landscape
The report also profiles major players in the global plasma protease C1-inhibitors treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Shire plc, CSL Limited, Sanquin and Pharming Group N.V.
The Global Plasma Protease C1-inhibitor Treatment Market is segmented as given below:
Global Plasma Protease C1-inhibitors Treatment Market, by Drug Class
C1-inhibitors
C1-esterase Inhibitor
Recombinant Inhibitor
Kallikrein Inhibitor (Kalbitor)
Selective Bradykinin B2 Receptor Antagonist (Firazyr)
Global Plasma Protease C1-inhibitors Treatment Market, by Dosage Type
Liquid/Injectable
Lyophilized
Global Plasma Protease C1-inhibitors Treatment Market, by Distribution Channel
Hospital Pharmacies
Independent Pharmacies and Outlets
Global Plasma Protease C1-inhibitors Treatment Market, By Geography
North America
U.S.
Canada
Europe
EU-5 Countries
BENELUX Countries
Rest of Europe
Latin America
Argentina
Brazil
Rest of Latin America
Rest of World
Australia
Israel
Rest of World Countries
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Plasma Protease C1-Inhibitor Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, 2015–2025
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis
4.8. Market Outlook
4.9. Regulatory Scenario
4.10. Pipeline Analysis and Patent Launch/Expiry
4.11. Therapeutic Application & Biological Activities: C1-Esterase Inhibitor
4.12. Global Number of Procedures of Hereditary Angioedema Disease
4.13. Brand Analysis Plasma Protease C1-Inhibitor Drugs
4.14. Product Portfolio of Human C1-INH Plasma Protein
4.15. Research Institutes Involved In Hereditary Angioedema/Others Disease
5. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Trends
5.3. Market Forecast By Drug Class, 2015–2025
5.3.1. C1-Inhibitor
5.3.1.1. C1-Esterase Inhibitor
5.3.1.2. Recombinant Inhibitor
5.3.2. Kallikrein Inhibitor (Kalbitor)
5.3.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
5.4. Market Attractiveness By Drug Class
6. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Dosage Type
6.1. Introduction & Definition
6.2. Market Forecast By Dosage Type, 2015–2025
6.2.1. Lyophilized
6.2.2. Liquid/Injectable
6.3. Market Attractiveness By Dosage Type
7. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Trends
7.3. Market Forecast By Distribution Channel , 2015–2025
7.3.1. Hospital Pharmacies
7.3.2. Independent Pharmacies and Outlets
7.4. Market Attractiveness By Distribution Channel
8. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Latin America
8.2.4. Rest of World
8.4. Market Attractiveness By Country/Region
9. North America Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Trends
9.2. Market Forecast By Drug Class, 2015–2025
9.2.1. C1-Inhibitor
9.2.1.1. C1-Esterase Inhibitor
9.2.1.2. Recombinant Inhibitor
9.2.2. Kallikrein Inhibitor (Kalbitor)
9.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
9.3. Market Forecast By Dosage Type, 2015–2025
9.3.1. Lyophilized
9.3.2. Liquid/Injectable
9.4. Market Forecast By Distribution Channel , 2015–2025
9.4.1. Hospital Pharmacies
9.4.2. Independent Pharmacies and Outlets
9.5. Market Forecast By Country, 2015–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Dosage Type
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Trends
10.2. Market Forecast By Drug Class, 2015–2025
10.2.1. C1-Inhibitor
10.2.1.1. C1-Esterase Inhibitor
10.2.1.2. Recombinant Inhibitor
10.2.2. Kallikrein Inhibitor (Kalbitor)
10.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
10.3. Market Forecast By Dosage Type, 2015–2025
10.3.1. Lyophilized
10.3.2. Liquid/Injectable
10.4. Market Forecast By Distribution Channel, 2015–2025
10.4.1. Hospital Pharmacies
10.4.2. Independent Pharmacies and Outlets
10.5. Market Forecast By Country, 2015–2025
10.5.1. EU-5 Countries
10.5.2. BENELUX Countries
10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Dosage Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Latin America Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Trends
11.2. Market Forecast By Drug Class, 2015–2025
11.2.1. C1-Inhibitor
11.2.1.1. C1-Esterase Inhibitor
11.2.1.2. Recombinant Inhibitor
11.2.2. Kallikrein Inhibitor (Kalbitor)
11.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
11.3. Market Forecast By Dosage Type, 2015–2025
11.3.1. Lyophilized
11.3.2. Liquid/Injectable
11.4. Market Forecast By Distribution Channel, 2015–2025
11.4.1. Hospital Pharmacies
11.4.2. Independent Pharmacies and Outlets
11.5. Market Forecast By Country, 2015–2025
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Dosage Type
11.6.3. By Distribution Channel
11.6.4. By Country
12. Rest of World Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Trends
12.2. Market Forecast By Drug Class, 2015–2025
12.2.1. C1-Inhibitor
12.2.1.1. C1-Esterase Inhibitor
12.2.1.2. Recombinant Inhibitor
12.2.2. Kallikrein Inhibitor (Kalbitor)
12.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.3. Market Forecast By Dosage Type, 2015–2025
12.3.1. Lyophilized
12.3.2. Liquid/Injectable
12.4. Market Forecast By Distribution Channel, 2015–2025
12.4.1. Hospital Pharmacies
12.4.2. Independent Pharmacies and Outlets
12.5. Market Forecast By Country, 2015–2025
12.5.1. Australia
12.5.2. Israel
12.5.3. Rest of World Countries
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Dosage Type
12.6.3. By Distribution Channel
12.6.4. By Country
13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis By Company (2016)
13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Shire plc
13.3.1.1. Overview (HQ, Employee Strength, Business Segments)
13.3.1.2. Financials
13.3.1.3. Recent Developments
13.3.1.4. Strategy
13.3.2. Pharming Group N.V.
13.3.2.1. Overview (HQ, Employee Strength, Business Segments)
13.3.2.2. Financials
13.3.2.3. Recent Developments
13.3.2.4. Strategy
13.3.3. Sanquin
13.3.3.1. Overview (HQ, Employee Strength, Business Segments)
13.3.3.2. Financials
13.3.3.3. Recent Developments
13.3.3.4. Strategy
13.3.4. CSL Limited
13.3.4.1. Overview (HQ, Employee Strength, Business Segments)
13.3.4.2. Financials
13.3.4.3. Recent Developments
13.3.4.4. Strategy
14. Key Take Aways
List of TablesTable 01: Pipeline Analysis-Phase 3-by Product/Drug Candidate, 2015-2017
Table 02: Pipeline Analysis-Phase 1 & 2 – Preclinical-by Product/Drug Candidate, 2014-2016
Table 03: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 04: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 05: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 06: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 07: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 08: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 09: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 10: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate
Table 11: Orphan Drug Exclusivity-by Approval & Expiry
Table 12: Orphan Drug Exclusivity-by Approval & Expiry
Table 13: Orphan Drug Exclusivity-by Approval & Expiry
Table 14: Product Portfolio of Human C1-INH Plasma Protein-by Sponsor/Company
Table 15: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 16: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015-2025
Table 17: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 18: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Region, 2015–2025
Table 20: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015-2025
Table 21: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 22: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 23: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 24: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 26: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 28: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 29: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 30: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country,
Table 31: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 32: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 33: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 34: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 35: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 36: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 37: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 38: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 39: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025